InvestorsHub Logo
Followers 33
Posts 5264
Boards Moderated 0
Alias Born 01/23/2019

Re: None

Sunday, 03/05/2023 11:07:19 AM

Sunday, March 05, 2023 11:07:19 AM

Post# of 424168
more PR from amarin, I guess they'll PR this tomorrow as well.

Amarin Announced New REDUCE-IT Data Showing Benefit Of VASCEPA/VAZKEPA In High-Risk Patients With A Recent Acute Coronary Syndrome Event
BENZINGA 11:03 AM ET 3/5/2023
Symbol Last Price Change
AMRN 1.95up 0 (0%)
QUOTES AS OF 04:00:00 PM ET 03/03/2023
Amarin Corporation plc (NASDAQ:AMRN) today announced a new analysis from the VASCEPA/VAZKEPA (icosapent ethyl) cardiovascular outcomes REDUCE-IT study showing the effectiveness of VASCEPA®/VAZKEPA® in patients with recent acute coronary syndrome (<12 months before randomization). This post-hoc analysis showed that icosapent ethyl (IPE) substantially and significantly reduced the risk of first and total ischemic events by 37% and 36% respectively in patients with recent acute coronary syndrome (ACS) without increasing bleeding, supporting early initiation of IPE after ACS. The data were presented at the American College of Cardiology's 72nd Annual Scientific Session together with the World Heart Federation'sWorld Congress of Cardiology in New Orleans, LA.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News